To clarify the role of NfL, GFAP and sCD163 as a sign for CNS damage presenting with NS, we stratified hospitalized COVID-19 patients according to the severe presence of NS during the acute stage of COVID-19 and self-referred NS three months after hospital discharge. This evidence concerns the gene CD163 and COVID-19.